-
公开(公告)号：WO2022197344A1
公开(公告)日：2022-09-22
申请号：PCT/US2022/000006
申请日：2022-03-18
IPC分类号： A61P35/00 , A61K47/54 , A61K31/704 , A61K39/395 , A61K47/69
摘要： Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising AR Prodrugs and methods of making the nanocarriers are disclosed herein. The AR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit A2aR. The AR Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：WO2022055542A1
公开(公告)日：2022-03-17
申请号：PCT/US2021/010039
申请日：2021-09-10
摘要： Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：WO2022265679A2
公开(公告)日：2022-12-22
申请号：PCT/US2022/000011
申请日：2022-06-17
IPC分类号： A61K38/21 , A61K47/68 , A61P35/00 , C07K7/08 , C07K14/56 , C07K16/28 , A61K38/212 , A61K47/6811 , A61K47/6849 , C07K16/2896 , C07K2319/33
摘要： Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
-
公开(公告)号：WO2021167703A1
公开(公告)日：2021-08-26
申请号：PCT/US2021/010005
申请日：2021-02-19
摘要： Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：WO2023091168A1
公开(公告)日：2023-05-25
申请号：PCT/US2022/000028
申请日：2022-11-17
IPC分类号： A61K47/54 , A61K31/704 , A61K47/62 , A61K47/69 , A61P35/00
摘要： Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising ICD Prodrugs and methods of making the nanocarriers are disclosed herein. The ICD prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that induce immunogenic cell death (ICD). The ICD Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
">
公开(公告)号：WO2021126281A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/000048
申请日：2020-12-21
IPC分类号： A61K31/4164 , A61K47/00 , C07J43/00 , A61K38/177 , A61K45/06 , A61K47/543 , A61K47/554 , A61K47/6911 , A61K9/1271 , C07J43/003
摘要： Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：WO2021096542A1
公开(公告)日：2021-05-20
申请号：PCT/US2020/000044
申请日：2020-11-12
摘要： Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.023 秒)
